secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2026-10-20T12:36:27+00:00
Accession:  0000899923-26-000094
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Myriad Genetics to sell prenatal health testing business to Labcorp for $210 million cash
--------------------------------------------------------------------------------

- Myriad Genetics agreed to sell its Prenatal Health testing business, including Prequel, Foresight, SneakPeek and FirstGene, to Labcorp for $210 million cash plus closing inventory value.
- Labcorp expects the acquisition to add about $160 million in revenue in year one, be slightly accretive to adjusted earnings in year one, and reach diagnostics segment margins by end of year two.
- The deal is subject to HSR and state health care approvals and is expected to close by early 2027; either party may terminate if not closed by Feb. 19, 2027, with extension to Oct. 19, 2027.
- Labcorp would pay Myriad a $10.5 million termination fee if the agreement is terminated due to failure to obtain certain regulatory clearances.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992326000094/0000899923-26-000094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992326000094/mygn-20261019.htm
  HTML page:      https://secwatch.observer/filing/0000899923-26-000094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer